Biophysical characterization and antineoplastic activity of new bis(thiosemicarbazonato) Cu(II) complexes.

Aiming to explore alternative mechanisms of cellular uptake and cytotoxicity, we have studied a new family of copper(II) complexes (CuL-CuL) with bis(thiosemicarbazone) (BTSC) ligands containing pendant protonable cyclic amines (morpholine and piperidine). Herein, we report on the synthesis and characterization of these new complexes, as well as on their biological performance (cytotoxic activity, cellular uptake, protein and DNA binding), in comparison with the parental CuATSM (ATSM=diacetyl-bis(N4-methylthiosemicarbazonate) complex without pendant cyclic amines. The new compounds have been characterized by a range of analytical techniques including ESI-MS, IR spectroscopy, cyclic voltammetry, reverse-phase HPLC and X-ray spectroscopy.

Chemical, radiochemical and biological studies of new gallium(III) complexes with hexadentate chelators.

New N4O2-donor acyclic chelators 2-[[2-[2-(3,5-dimethylpyrazol-1-yl)ethyl-[2-[(2-hydroxyphenyl)methylamino]ethyl]amino]ethylamino]methyl]phenol (H2L(pz*,NH)) and 2-[[2-[2-[(2-hydroxyphenyl)methylamino]ethyl-(2-pyridylmethyl)amino]ethylamino]methyl]phenol (H2L(py,NH)) were obtained upon introduction of pyridyl or pyrazolyl coordinating units at the central nitrogen atom of diethylenetriamine (dien) and by functionalization of its terminal amines with phenol groups. The coordination behavior of H2L(pz*,NH) and H2L(py,NH) was evaluated towards (nat)Ga/(67)Ga, aiming to assess their suitability to obtain Ga(iii) chelates relevant for biomedical applications. Single crystal X-ray diffraction analysis of the complexes [GaL(pz*,NH)](ClO4) and [GaL(py,NH)](ClO4) confirmed the presence of N4O2-hexadentate chelators with the phenoxide groups coordinated cis relatively to the pyridyl/pyrazolyl arms.

Bisphosphonates as radionuclide carriers for imaging or systemic therapy.

Bisphosphonates (BP's), biologically stable analogs of naturally occurring pyrophosphates, became the treatment of choice for pathologic conditions characterized by increased osteoclast-mediated bone resorption, namely Paget's disease, osteoporosis and tumor bone disease. Moreover, the clinical success of BP's is also associated with their use in (99m)Tc-based radiopharmaceuticals for bone imaging. In addition to the successful delivery of (99m)Tc (γ-emitter) to bone, BP's have also been used to deliver β(-)-particle emitting radiometals (e.